Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised SEB in connection with the issuance of Additional Tier 1 Capital of USD 500 million
Mandate

Vinge has advised SEB in connection with the issuance of Additional Tier 1 Capital of USD 500 million

June 07, 2022 Banking and Finance Capital Markets and Public M&A

Vinge has advised Skandinaviska Enskilda Banken AB (publ) as to Swedish law in connection with the issuance of Additional Tier 1 Capital (AT1) of USD 500 million to optimise its capital structure.

The issuance is in the form of a debt instrument with automatic conversion into Class A shares if the Common Equity Tier 1 capital ratio of the bank falls below a certain level. The instruments will be listed on Euronext Dublin.

Vinge’s team consisted of Albert Wållgren, David Andersson and Arvid Weimers.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025